Ivana R Ferrer
Overview
Explore the profile of Ivana R Ferrer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu D, Yao H, Ferrer I, Ford M
Am J Transplant
. 2024 Mar;
24(8):1369-1381.
PMID: 38552961
Recently published studies in both murine models and a meta-analysis of non-human primate renal transplant studies showed that anti-CD154 reagents conferred a significant survival advantage over CD40 blockers in both...
2.
West H, Davies J, Henderson S, Adegun O, Ward S, Ferrer I, et al.
Cell Rep
. 2022 May;
39(7):110819.
PMID: 35584681
T cell pathology in the skin leads to monocyte influx, but we have little understanding of the fate of recruited cells within the diseased niche, or the long-term impact on...
3.
Dertschnig S, Evans P, Santos E Sousa P, Manzo T, Ferrer I, Stauss H, et al.
J Clin Invest
. 2020 Jan;
130(4):1896-1911.
PMID: 31917684
Acute graft-versus-host disease (GVHD) is initially triggered by alloreactive T cells, which damage peripheral tissues and lymphoid organs. Subsequent transition to chronic GVHD involves the emergence of autoimmunity, although the...
4.
Ferrer I, West H, Henderson S, Ushakov D, Santos E Sousa P, Strid J, et al.
Sci Immunol
. 2019 Aug;
4(38).
PMID: 31444235
A dense population of embryo-derived Langerhans cells (eLCs) is maintained within the sealed epidermis without contribution from circulating cells. When this network is perturbed by transient exposure to ultraviolet light,...
5.
Santos E Sousa P, Cire S, Conlan T, Jardine L, Tkacz C, Ferrer I, et al.
JCI Insight
. 2018 Mar;
3(5).
PMID: 29515032
Graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic stem cell transplantation induced by the influx of donor-derived effector T cells (TE) into peripheral tissues. Current treatment strategies rely on...
6.
Ferrer I, Hester J, Bushell A, Wood K
Immunol Rev
. 2014 Feb;
258(1):102-16.
PMID: 24517428
Organ transplantation results in the activation of both innate and adaptive immune responses to the foreign antigens. While these responses can be limited with the use of systemic immunosuppressants, the...
7.
Liu D, Ferrer I, Konomos M, Ford M
J Immunol
. 2013 Jul;
191(4):1957-64.
PMID: 23858029
Current models of CD4(+) T cell help suggest a major role for CD154 binding to CD40 expressed on dendritic cells, with a lesser role for direct T:T interactions via CD40...
8.
Ferrer I, Liu D, Pinelli D, Koehn B, Stempora L, Ford M
J Immunol
. 2012 Sep;
189(9):4387-95.
PMID: 23002440
Blockade of the CD40/CD154 pathway remains one of the most effective means of promoting graft survival following transplantation. However, the effects of CD40/CD154 antagonism on dendritic cell (DC) phenotype and...
9.
Ferrer I, Wagener M, Song M, Ford M
PLoS One
. 2012 Jul;
7(7):e40559.
PMID: 22792369
CD154/CD40 blockade combined with donor specific transfusion remains one of the most effective therapies in prolonging allograft survival. Despite this, the mechanisms by which these pathways synergize to prevent rejection...
10.
Ferrer I, Wagener M, Song M, Kirk A, Larsen C, Ford M
Proc Natl Acad Sci U S A
. 2011 Dec;
108(51):20701-6.
PMID: 22143783
Blockade of the CD40/CD154 pathway potently attenuates T-cell responses in models of autoimmunity, inflammation, and transplantation. Indeed, CD40 pathway blockade remains one of the most powerful methods of prolonging graft...